Reconciling a new comparative effectiveness research (CER) agency with scientific standards established in existing regulations would enable government agencies to share a consistent framework for making decisions based on CER. It would provide the kind of level playing field and clear guidelines that are needed to spur medical product developers and private payers to generate more of their own comparative evidence.
Reprinted with the permission of the American Enterprise Institute for Public Policy Research, Washington, D.C.